https://www.live-feeds.com/feed/viking-therapeutics-skyrockets-on-obesity-drug-data-eli-lilly-novo-fallContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/viking-therapeutics-skyrockets-on-obesity-drug-data-eli-lilly-novo-fallhttps://www.live-feeds.com/feed/viking-therapeutics-skyrockets-on-obesity-drug-data-eli-lilly-novo-fall#u82155Thu, 24 Sep 2026 03:50:29 +0000Viking Therapeutics shares rose up to 36% following positive topline results from a maintenance study of its GLP-1/GIP agonist, VK2735. The drug demonstrated strong weight-loss retention with once-a-month dosing regimens. Market reaction saw Viking stock skyrocket while competitors Eli Lilly and Novo Nordisk declined. One report indicates the treatment achieved 22% more weight loss than a placebo by week 33 without reaching a plateau. Recent trading data shows the stock holding above a key support level of $32.11 despite a minor slip of 1.86%.Why it mattersVK2735 competes in the high-growth ob